Skip to content

Study · Systematic review · n = 2,614 · 2025

8 results

Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.

Zufry H, Hariyanto TI

Diabetes, obesity & metabolism27 Aug 2025Cited by 2 (Europe PMC)

PMID40859897 (opens in a new tab)DOI10.1111/dom.70073 (opens in a new tab)PepBankPUB-40859897
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In Asian adults with overweight or obesity, pooled RCTs showed semaglutide 2.4 mg reduced body weight more than placebo (MD -8.20%, 95% CI -10.06 to -6.35).

    In plain wordsIn Asian adults with overweight or obesity, pooled trials found semaglutide 2.4 mg led to more weight loss than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody weight, mean difference versus placebo
    Study

    n = 2,614

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Mean difference in body weight
    −8.2%
    semaglutide 2.4 mg vs placebo
    95% CI
    −10.06 to −6.35%
    body weight

    Source sentences

    Summary
    significantly greater reductions in body weight (MD: -8.20%; 95% confidence interval [CI]: -10.06 to -6.35; I2 = 84%
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.
  2. 02HumanSystematic reviewEfficacy outcome

    In Asian adults with overweight or obesity, pooled RCTs showed semaglutide 2.4 mg reduced waist circumference more than placebo (MD -6.47 cm, 95% CI -8.26 to -4.68).

    In plain wordsIn Asian adults with overweight or obesity, pooled trials found semaglutide 2.4 mg reduced waist size more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseWaist circumference, mean difference versus placebo
    Study

    n = 2,614

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Mean difference in waist circumference
    −6.47 cm
    semaglutide 2.4 mg vs placebo
    95% CI
    −8.26 to −4.68 cm
    waist circumference

    Source sentences

    Summary
    waist circumference (MD: -6.47 cm; 95% CI: -8.26 to -4.68; I2 = 84%
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.
  3. 03HumanSystematic reviewEfficacy outcome

    In Asian adults with overweight or obesity, pooled RCTs showed semaglutide 2.4 mg reduced BMI more than placebo (MD -3.22 kg/m2, 95% CI -4.01 to -2.44).

    In plain wordsIn Asian adults with overweight or obesity, pooled trials found semaglutide 2.4 mg lowered BMI more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index, mean difference versus placebo
    Study

    n = 2,614

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Mean difference in BMI
    −3.22 kg/m2
    semaglutide 2.4 mg vs placebo
    95% CI
    −4.01 to −2.44 kg/m2
    BMI

    Source sentences

    Summary
    body mass index (MD: -3.22 kg/m2; 95% CI: -4.01 to -2.44; I2 = 66%
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.
  4. 04HumanSystematic reviewEfficacy outcome

    In Asian adults with overweight or obesity, pooled RCTs showed semaglutide 2.4 mg reduced systolic blood pressure more than placebo (MD -3.46 mmHg, 95% CI -5.29 to -1.62).

    In plain wordsIn Asian adults with overweight or obesity, pooled trials found semaglutide 2.4 mg lowered systolic blood pressure more than placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseSystolic blood pressure, mean difference versus placebo
    Study

    n = 2,614

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Measurements

    Mean difference in systolic blood pressure
    −3.46 mmHg
    semaglutide 2.4 mg vs placebo
    95% CI
    −5.29 to −1.62 mmHg
    systolic blood pressure

    Source sentences

    Summary
    systolic blood pressure (MD: -3.46 mmHg; 95% CI: -5.29 to -1.62; I2 = 28%) compared to placebo
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.
  5. 05HumanSystematic reviewEfficacy outcome

    In Asian adults with overweight or obesity, a higher proportion on semaglutide 2.4 mg than on placebo achieved weight loss exceeding 5%.

    In plain wordsIn Asian adults with overweight or obesity, more people on semaglutide 2.4 mg than on placebo lost more than 5% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss above 5%
    Study

    n = 2,614

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A higher proportion of participants in semaglutide 2.4 mg achieved weight loss exceeding 5%
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.
  6. 06HumanSystematic reviewEfficacy outcome

    In Asian adults with overweight or obesity, a higher proportion on semaglutide 2.4 mg than on placebo achieved weight loss exceeding 10%.

    In plain wordsIn Asian adults with overweight or obesity, more people on semaglutide 2.4 mg than on placebo lost more than 10% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss above 10%
    Study

    n = 2,614

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A higher proportion of participants in semaglutide 2.4 mg achieved weight loss exceeding 5%, 10% and 15%.
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.
  7. 07HumanSystematic reviewEfficacy outcome

    In Asian adults with overweight or obesity, a higher proportion on semaglutide 2.4 mg than on placebo achieved weight loss exceeding 15%.

    In plain wordsIn Asian adults with overweight or obesity, more people on semaglutide 2.4 mg than on placebo lost more than 15% of their weight.

    Peptide
    Semaglutide
    Outcome
    IncreaseWeight loss above 15%
    Study

    n = 2,614

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    A higher proportion of participants in semaglutide 2.4 mg achieved weight loss exceeding 5%, 10% and 15%.
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.
  8. 08HumanSystematic reviewSafety outcome

    In Asian adults with overweight or obesity, gastrointestinal symptoms were the most commonly reported adverse effects of semaglutide 2.4 mg, generally mild to moderate and self-limiting.

    In plain wordsIn Asian adults with overweight or obesity, stomach and gut symptoms were the most common side effects of semaglutide 2.4 mg, mostly mild.

    Peptide
    Semaglutide
    Outcome
    Direction not reportedGastrointestinal adverse effects
    Study

    n = 2,614

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    2.4 mg · subcutaneousAs given in this study (human).

    Source sentences

    Summary
    Gastrointestinal symptoms were the most commonly reported adverse effects, generally mild to moderate and self-limiting.
    2 context sentences
    Summary · context
    Eligible studies were randomised controlled trials (RCTs) comparing semaglutide 2.4 mg with placebo in overweight or obese Asian individuals.
    Summary · context
    Five RCTs involving 2614 participants met the inclusion criteria.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.